Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World

瑞戈非尼 医学 内科学 结直肠癌 不利影响 队列 队列研究 观察研究 肿瘤科 外科 癌症
作者
Qi Zhang,Mifen Chen,Zhenghang Wang,Changsong Qi,Yanshuo Cao,Junyan Zhang,Zhi Peng,Xicheng Wang,Ming Lu,Lin Shen,Jian Li
出处
期刊:Clinical Colorectal Cancer [Elsevier BV]
卷期号:21 (3): e152-e161 被引量:8
标识
DOI:10.1016/j.clcc.2022.01.007
摘要

BackgroundRegorafenib and fruquintinib are tyrosine kinase inhibitors that are recommended for refractory colorectal cancer (CRC) in China. However, to date, no head-to-head trials have been conducted to guide clinical practice.Methods and PatientsAn ambispective observational cohort study was conducted in Beijing Cancer Hospital. Patients with metastatic CRC who received regorafenib or fruquintinib were retrospectively collected between January 2018 and April 2020, and prospectively enrolled between May 2020 and February 2021. The primary outcome was time-to-treatment failure (TTF), and secondary outcomes were overall survival (OS) and adverse events. An additional goal of the study was to explore the appropriate sequence of regorafenib and fruquintinib treatment.ResultsA total of 366 patients with metastatic CRC were enrolled to receive regorafenib (n = 260) or fruquintinib (n = 106) between January 2018 and February 2021. No difference was observed for median TTF (regorafenib 2.7 months vs. fruquintinib 3.1 months, P = .200) or median OS (regorafenib 13.8 months vs. fruquintinib 11.3 months, P = .527). The propensity score analysis showed similar results for median TTF and median OS between the 2 groups, as did the results of subgroup analysis for prospective set (n = 146). For sequence analysis, patients with regorafenib followed by fruquintinib (n = 84) showed longer OS than that with the reverse (n = 29) (28.1 months vs. 18.4 months, P = .024). Most patients tolerated regorafenib at a reduced dose (93.1%), and most patients tolerated fruquintinib at a standard dose (68.9%). The incidences of most adverse events were similar between the two groups, while any grade of hand-foot skin reaction and hyperbilirubinemia were more frequently observed in the regorafenib group and ≥grade 3 hypertension was more common in the fruquintinib group.ConclusionRegorafenib and fruquintinib had similar efficacy and toxicity profiles with various frequency. Regorafenib followed by fruquintinib showed longer OS than the reverse, but the sequence needs to be further confirmed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
哈哈完成签到,获得积分10
5秒前
6秒前
善学以致用应助D_采纳,获得10
8秒前
风清扬应助社科狗采纳,获得50
8秒前
科研通AI5应助李天王采纳,获得20
9秒前
9秒前
kingking完成签到,获得积分10
11秒前
丘比特应助SSS水鱼采纳,获得10
11秒前
11秒前
11秒前
ll完成签到,获得积分10
12秒前
风味烤羊腿完成签到,获得积分0
13秒前
13秒前
baibai完成签到,获得积分10
14秒前
猪猪hero应助魏开铭采纳,获得10
15秒前
大模型应助一只奇怪的鸟采纳,获得10
15秒前
16秒前
lyh发布了新的文献求助10
16秒前
18秒前
李健应助科研通管家采纳,获得10
18秒前
18秒前
wanci应助科研通管家采纳,获得10
19秒前
852应助科研通管家采纳,获得10
19秒前
ll应助科研通管家采纳,获得10
19秒前
19秒前
19秒前
19秒前
19秒前
小麻花完成签到,获得积分10
19秒前
量子星尘发布了新的文献求助10
20秒前
humble完成签到 ,获得积分10
20秒前
木子木完成签到,获得积分10
21秒前
22秒前
Wind发布了新的文献求助10
22秒前
和谐的映梦完成签到,获得积分10
22秒前
彼岸花完成签到,获得积分10
23秒前
24秒前
迟迟完成签到,获得积分10
25秒前
澡雪发布了新的文献求助10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975516
求助须知:如何正确求助?哪些是违规求助? 3519930
关于积分的说明 11200130
捐赠科研通 3256278
什么是DOI,文献DOI怎么找? 1798183
邀请新用户注册赠送积分活动 877425
科研通“疑难数据库(出版商)”最低求助积分说明 806320